In the phase 3 J-ALEX study in Japanese patients with ALK TKI-naive NSCLC, alectinib demonstrated longer progression-free survival (PFS) vs crizotinib (median 34.1 vs 10.2 months, hazard ratio [HR], 0.37) [4, 5]. Here, ALK is linked to non-small cell lung carcinoma.